胃腺癌新辅助降期的预后意义
单中心2007–2017年384例胃腺癌根治性胃切除术患者中,141例接受新辅助化疗,86例(58.1%)实现病理降期;降期患者总生存优于未降期者,降期超过3个分期是总生存的最强独立预测因素(HR 0.17)。
要点
- 新辅助化疗后病理降期与总生存改善相关。
- 降期超过3个分期是总生存的最强独立预测因素。
- 逐期比较中ypTNM组总生存显著优于pTNM组。
核心结论
- 病理分期比临床分期更准确预测预后,降期患者复发率更低且总生存改善。
研究设计与样本
- 单中心2007至2017年连续胃腺癌患者,行次全或全胃切除联合D2淋巴结清扫。
- 共384例接受胃切除术,其中141例接受新辅助化疗。
- 按TNM第八版进行ypTNM与pTNM的逐期比较。
主要发现
- 141例新辅助化疗患者中86例(58.1%)实现病理降期。
- 降期患者总生存优于未降期者(未报告 vs 66个月,P < .001)。
- 降期超过3个分期是总生存的最强独立预测因素(HR 0.17;95%CI 0.062-0.44)。
- 逐期比较中ypTNM组总生存显著优于pTNM组。
临床怎么用
- 新辅助化疗后病理降期可用于评估胃腺癌患者预后。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Neoadjuvant chemotherapy is established in the treatment of gastric adenocarcinoma. Histopathological regression may have important prognostic implications. There are little data comparing clinical outcomes of patients with gastric adenocarcinoma that received neoadjuvant treatment and those neoadjuvant naive. The aim of this study is to determine the impact of neoadjuvant chemotherapy upon prognosis of patients being treated for gastric adenocarcinoma. METHODS: Consecutive patients with gastric cancer from a single center between 2007 and 2017 were evaluated. Patients were treated with either a subtotal or total gastrectomy with D2 lymphadenectomy. Stage-by-stage comparison of the extent of pathological downstaging was conducted for patients who received neoadjuvant treatment (ypTNM) and those who did not (pTNM) using the TNM eighth edition. RESULTS: Overall, 384 patients underwent gastrectomy, 141 patients received neoadjuvant chemotherapy, and 86 patients (58.1%) were downstaged. Downstaged patients had improved overall survival compared to patients who did not respond to neoadjuvant chemotherapy (not reported vs 66 months, P < .001). Downstaging by >3 stages was the strongest independent predictor of overall survival (hazard ratio: 0.17; 95% confidence interval 0.062-0.44). Overall survival was significantly better among patients in the ypTNM groups when a stage-by-stage comparison was performed with the pTNM group. CONCLUSION: Pathological stage is a more accurate predictor of prognosis compared clinical stage with downstaged patients benefiting from lower recurrence rates and improved overall survival. Patients downstaged due to neoadjuvant chemotherapy may potentially have more favorable clinical outcomes compared to stage-matched patients who did not receive this.
引用
- Prasad P, Sivaharan A, Navidi M, et al. Significance of neoadjuvant downstaging in gastric adenocarcinoma. Surgery. 2022. PMID: 35400501. doi:10.1016/j.surg.2022.03.005
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。